neuroendocrine tumours (pNET/epNET)
Oncology · 2025–2025
1decision
1medicine
1carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cabozantinib Treatment of adult patients with unresectable locally advanced or metastatic well- or moderately-differentiated pancreatic neuroendocrine tumour (pNET) or… | Jul 2025 | Recommended | 2 individuals Rare Cancers Australia · NeuroEndocrine Cancer Australia · Medical Oncology Group |
Who spoke
Rare Cancers Australia · NeuroEndocrine Cancer Australia · Medical Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.